Literature DB >> 5545124

Glomerular deposition of properdin in acute and chronic glomerulonephritis with hypocomplementemia.

N G Westberg, G B Naff, J T Boyer, A F Michael.   

Abstract

Kidney tissue from 97 patients was studied by immunofluorescent techniques using antiserum to purified properdin. All patients with acute poststreptococcal glomerulonephritis showed deposition of properdin and the third component of complement (C3), either as "humps" on the basement membrane, or in the mesangium. In all cases of chronic membranoproliferative glomerulonephritis, properdin and C3 were localized in the glomeruli, most commonly in a lobular pattern on the basement membrane. Activation of C3 by the properdin system may explain the depressed serum levels of C3 and terminal complement components even though levels of earlier components are normal, and the deposition of C3, often without immunoglobulins, in the kidneys of patients with acute glomerulonephritis or chronic membranoproliferative glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5545124      PMCID: PMC291972          DOI: 10.1172/JCI106534

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  Properties of highly purified human properdin.

Authors:  J Ensky; C F Hinz; E W Todd; R J Wedgwood; J T Boyer; I H Lepow
Journal:  J Immunol       Date:  1968-01       Impact factor: 5.422

2.  Serum C'3 lytic system in patients with glomerulonephritis.

Authors:  R E Spitzer; E H Vallota; J Forristal; E Sudora; A Stitzel; N C Davis; C D West
Journal:  Science       Date:  1969-04-25       Impact factor: 47.728

3.  Decreased properdin activity in acute glomerulonephritis.

Authors:  H Gewurz; R J Pickering; G Naff; R Snyderman; S E Mergenhagen; R A Good
Journal:  Int Arch Allergy Appl Immunol       Date:  1969

4.  The pathogenesis of glomerulonephritis.

Authors:  F J Dixon
Journal:  Am J Med       Date:  1968-04       Impact factor: 4.965

5.  Complement inactivation by serum from patients with acute and hypocomplementemic chronic glomerulonephritis.

Authors:  R J Pickering; H Gewurz; R A Good
Journal:  J Lab Clin Med       Date:  1968-08

6.  Fluorescent antibody staining. 3. Preparation of fluorescein-isothiocyanate-labeled antibodies.

Authors:  B T Wood; S H Thompson; G Goldstein
Journal:  J Immunol       Date:  1965-08       Impact factor: 5.422

7.  Acute poststreptococcal glomerulonephritis: immune deposit disease.

Authors:  A F Michael; K N Drummond; R A Good; R L Vernier
Journal:  J Clin Invest       Date:  1966-02       Impact factor: 14.808

8.  Beta-1C-globulin: metabolism in glomerulonephritis.

Authors:  C A Alper; A S Levin; F S Rosen
Journal:  Science       Date:  1966-07-08       Impact factor: 47.728

9.  Acute serum sickness nephritis in the rabbit. An immune deposit disease.

Authors:  A J Fish; A F Michael; R L Vernier; R A Good
Journal:  Am J Pathol       Date:  1966-12       Impact factor: 4.307

10.  Evidence for in vivo breakdown of beta-10-globulin in hypocomplementemic glomerulonephritis.

Authors:  C D West; S Winter; J Forristal; J M McConville; N C Davis
Journal:  J Clin Invest       Date:  1967-04       Impact factor: 14.808

View more
  38 in total

1.  Role of properdin in kidney diseases.

Authors:  R M Nakamura
Journal:  Calif Med       Date:  1972-05

2.  Membranoproliferative glomerulonephritis. Localization of early components of complement in glomerular deposits.

Authors:  B K Davis; T Cavallo
Journal:  Am J Pathol       Date:  1976-08       Impact factor: 4.307

3.  Influence of dietary restriction on immunologic function and renal disease in (NZB x NZW) F1 mice.

Authors:  G Fernandes; P Friend; E J Yunis; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1978-03       Impact factor: 11.205

4.  Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.

Authors:  J A Charlesworth; D G Williams; E Sherington; P J Lachmann; D K Peters
Journal:  J Clin Invest       Date:  1974-06       Impact factor: 14.808

5.  Complement activation by Coccidioides immitis: in vitro and clinical studies.

Authors:  J N Galgiani; P Yam; L D Petz; P L Williams; D A Stevens
Journal:  Infect Immun       Date:  1980-06       Impact factor: 3.441

6.  Selective binding of IgG4 and other negatively charged plasma proteins in normal and diabetic human kidneys.

Authors:  T Melvin; Y Kim; A F Michael
Journal:  Am J Pathol       Date:  1984-06       Impact factor: 4.307

7.  The secretory immune system and renal disease.

Authors:  R S Dobrin; F E Knudson; A F Michael
Journal:  Clin Exp Immunol       Date:  1975-08       Impact factor: 4.330

8.  C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.

Authors:  K Whaley; P H Schur; S Ruddy
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

9.  Glomerular complement components in human glomerulonephritis.

Authors:  P J Verroust; C B Wilson; N R Cooper; T S Edgington; F J Dixon
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

10.  Glomerulonephritis with mesangial deposits of IgA unassociated with systemic disease.

Authors:  A Katz; B J Underdown; J O Minta; I H Lepow
Journal:  Can Med Assoc J       Date:  1976-02-07       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.